Abstract
By assessing how drug/new chemical entity (NCE) cytotoxicity is affected when their metabolic pathways are inhibited or activated, the metabolic pathways that activate versus detoxify drugs/NCEs can be identified. Reactive metabolites contributing to cytotoxicity can also be identified. In the following, the drug metabolizing enzyme inhibitors and activators used in vitro with freshly isolated rat hepatocytes for the accelerated cytotoxicity mechanism screening (ACMS) of drugs/NCEs (a technique used in our laboratory) are reviewed and, this technique is useful for determining in vivo rat hepatotoxicity mechanisms. The enzyme inhibitors/activators have been chosen on the basis of their selectivity, modulator effectiveness, and their lack of toxicity. The use of these inhibitors/activators with human hepatocytes or subcellular fractions for assessing human hepatotoxicity mechanisms is also reviewed.
Keywords: cytochrome p-450, hepatotoxicity, glucuronosyltransferase, arylamine n-acetyltransferase, sulfotransferases, glutathione transferase, coenzyme a-transferases, enzyme Inhibitors
Current Drug Metabolism
Title: Accelerated Cytotoxicity Mechanism Screening Using Drug Metabolising Enzyme Modulators
Volume: 6 Issue: 2
Author(s): P. J. O'Brien and A. G. Siraki
Affiliation:
Keywords: cytochrome p-450, hepatotoxicity, glucuronosyltransferase, arylamine n-acetyltransferase, sulfotransferases, glutathione transferase, coenzyme a-transferases, enzyme Inhibitors
Abstract: By assessing how drug/new chemical entity (NCE) cytotoxicity is affected when their metabolic pathways are inhibited or activated, the metabolic pathways that activate versus detoxify drugs/NCEs can be identified. Reactive metabolites contributing to cytotoxicity can also be identified. In the following, the drug metabolizing enzyme inhibitors and activators used in vitro with freshly isolated rat hepatocytes for the accelerated cytotoxicity mechanism screening (ACMS) of drugs/NCEs (a technique used in our laboratory) are reviewed and, this technique is useful for determining in vivo rat hepatotoxicity mechanisms. The enzyme inhibitors/activators have been chosen on the basis of their selectivity, modulator effectiveness, and their lack of toxicity. The use of these inhibitors/activators with human hepatocytes or subcellular fractions for assessing human hepatotoxicity mechanisms is also reviewed.
Export Options
About this article
Cite this article as:
O'Brien J. P. and Siraki G. A., Accelerated Cytotoxicity Mechanism Screening Using Drug Metabolising Enzyme Modulators, Current Drug Metabolism 2005; 6 (2) . https://dx.doi.org/10.2174/1389200053586082
DOI https://dx.doi.org/10.2174/1389200053586082 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immunoregulatory Impact of Food Antioxidants
Current Pharmaceutical Design Combined Therapies of Bone Disease with Bisphosphonates
Current Pharmaceutical Design The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Current Trends in the Application of Nanoparticles in Drug Delivery
Current Medicinal Chemistry Anti-Tumor Monoclonal Antibodies in Conjunction with β-Glucans: A Novel Anti- Cancer Immunotherapy
Current Medicinal Chemistry Chemical Characterization and Antioxidant Potential of <i>Athroisma proteiformis</i> Essential Oil
The Natural Products Journal Plant Natural Products in Anticancer Drug Discovery
Current Organic Chemistry Anti-Cancer Effect of α-Solanine by Down-Regulating S100P Expression in Colorectal Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery HDAC as a Therapeutic Target for Treatment of Endometrial Cancers
Current Pharmaceutical Design Doxorubicin vs. ladirubicin: methods for improving osteosarcoma treatment
Mini-Reviews in Medicinal Chemistry Understanding Molecular Pathways and Targets of Brachyury in Epithelial-mesenchymal Transition (EMT) in Human Cancers
Current Cancer Drug Targets Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: From a Clinical to a Molecular Association
Current Pharmaceutical Design Nanoparticle Albumin - Bound (NAB) Technology is a Promising Method for Anti-Cancer Drug Delivery
Recent Patents on Anti-Cancer Drug Discovery Gene Expression Significance in Personalized Medicine of Non-small Cell Lung Cancer and Gene Expression Analyzing Platforms
Current Drug Metabolism CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies
Current Cancer Drug Targets Changes in and Impact of the Death Review Process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
Reviews on Recent Clinical Trials Current Systemic Treatment and Emerging Therapeutic Strategies in Pancreatic Adenocarcinoma
Current Clinical Pharmacology Potential Cardio-Protective Agents: A Resveratrol Review (2000-2019)
Current Pharmaceutical Design Vitamin D and the Epigenetic Machinery in Colon Cancer
Current Medicinal Chemistry Pharmacogenomics: The Influence of Genomic Variation on Drug Response
Current Topics in Medicinal Chemistry